These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Phenotype-genotype correlation of in vitro SN-38 (active metabolite of irinotecan) and bilirubin glucuronidation in human liver tissue with UGT1A1 promoter polymorphism. Iyer L, Hall D, Das S, Mortell MA, Ramírez J, Kim S, Di Rienzo A, Ratain MJ. Clin Pharmacol Ther; 1999 May; 65(5):576-82. PubMed ID: 10340924 [Abstract] [Full Text] [Related]
6. Involvement of UDP-glucuronosyltransferase activity in irinotecan-induced delayed-onset diarrhea in rats. Onoue M, Kurita A, Kado S, Matsumoto T, Kaneda N, Uchida K, Kato I, Yokokura T. Cancer Chemother Pharmacol; 2008 Apr; 61(4):595-605. PubMed ID: 17549477 [Abstract] [Full Text] [Related]
7. UGT1A10 is responsible for SN-38 glucuronidation and its expression in human lung cancers. Oguri T, Takahashi T, Miyazaki M, Isobe T, Kohno N, Mackenzie PI, Fujiwara Y. Anticancer Res; 2004 Apr; 24(5A):2893-6. PubMed ID: 15517893 [Abstract] [Full Text] [Related]
8. Glucuronidation of 7-ethyl-10-hydroxycamptothecin (SN-38), an active metabolite of irinotecan (CPT-11), by human UGT1A1 variants, G71R, P229Q, and Y486D. Jinno H, Tanaka-Kagawa T, Hanioka N, Saeki M, Ishida S, Nishimura T, Ando M, Saito Y, Ozawa S, Sawada J. Drug Metab Dispos; 2003 Jan; 31(1):108-13. PubMed ID: 12485959 [Abstract] [Full Text] [Related]
9. The contribution of intestinal UDP-glucuronosyltransferases in modulating 7-ethyl-10-hydroxy-camptothecin (SN-38)-induced gastrointestinal toxicity in rats. Tallman MN, Miles KK, Kessler FK, Nielsen JN, Tian X, Ritter JK, Smith PC. J Pharmacol Exp Ther; 2007 Jan; 320(1):29-37. PubMed ID: 17003228 [Abstract] [Full Text] [Related]
12. The UGT1A1*28 polymorphism correlates with erlotinib's effect on SN-38 glucuronidation. Liu Y, Ramírez J, House L, Ratain MJ. Eur J Cancer; 2010 Jul; 46(11):2097-103. PubMed ID: 20580994 [Abstract] [Full Text] [Related]